首页> 外文OA文献 >Raised plasma glutathione S-transferase values in hyperthyroidism and in hypothyroid patients receiving thyroxine replacement: evidence for hepatic damage.
【2h】

Raised plasma glutathione S-transferase values in hyperthyroidism and in hypothyroid patients receiving thyroxine replacement: evidence for hepatic damage.

机译:甲状腺功能亢进症和接受甲状腺素替代治疗的甲状腺功能减退患者的血浆谷胱甘肽S-转移酶值升高:肝损害的证据。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Using plasma glutathione S-transferase measurements hepatocellular integrity was assessed in groups of hyperthyroid and hypothyroid patients before and after treatment. Ten of 14 hyperthyroid patients had clearly raised plasma glutathione S-transferase values at presentation and in each patient treatment with either iodine-131 or carbimazole resulted in a significant fall in glutathione S-transferase. The eight hypothyroid patients had normal glutathione S-transferase values at presentation and all showed a significant increase in these after thyroxine replacement therapy. In three of these patients in whom standard doses of replacement therapy were associated with a raised free thyroxine (T4) concentration but normal total and free triiodothyronine (T3) values glutathione S-transferase was increased. Similar though less consistent changes were seen in the results of standard chemical tests of liver function. It is concluded that hyperthyroidism may produce subclinical liver damage in a high proportion of patients and that this resolves with effective treatment. More important, the data suggest that hypothyroid patients receiving thyroxine replacement therapy may have similar subclinical liver damage. Patients receiving thyroxine should be monitored by the measurement of free, not total hormone concentrations, and in those in whom free T4 is raised the dose of thyroxine should be reduced. It would also be expedient to include periodic biochemical assessment of liver function in patients receiving thyroxine.
机译:使用血浆谷胱甘肽S-转移酶测量来评估甲亢和甲状腺功能减退患者组治疗前后的肝细胞完整性。 14名甲状腺功能亢进患者中有10名在就诊时明显升高了血浆谷胱甘肽S-转移酶值,每位患者用碘131或卡咪唑治疗均会导致谷胱甘肽S-转移酶显着下降。八名甲状腺功能低下的患者在就诊时具有正常的谷胱甘肽S-转移酶值,并且在甲状腺素替代治疗后所有患者的谷胱甘肽S-转移酶值均显着增加。在其中三例患者中,标准剂量的替代治疗与游离甲状腺素(T4)浓度升高相关,但正常总和游离三碘甲状腺素(T3)值增加了谷胱甘肽S-转移酶。在肝功能的标准化学测试结果中发现了相似但不太一致的变化。结论是甲状腺功能亢进症可能在很大比例的患者中产生亚临床肝损害,并且可以通过有效的治疗来解决。更重要的是,数据表明接受甲状腺素替代治疗的甲状腺功能减退患者可能具有类似的亚临床肝损害。接受甲状腺素治疗的患者应通过测量游离激素而不是总激素浓度进行监测,对于游离T4升高的患者,应减少甲状腺素的剂量。包括接受甲状腺素治疗的患者的肝功能的定期生化评估也将是有利的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号